Early loss of axons limits the therapeutic window in a mouse model of spinal muscular atrophy
Current treatments for spinal muscular atrophy have significantly improved patient prognosis, but still fall short of a full cure, particularly when administered after symptom onset. To improve future therapies, it is essential to identify the early pathological events that currently limit treatment efficacy. Here we...